Valneva Valuation Multiples

Valneva Overview

About Valneva

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

Founded

1999

HQ

Employees

713

Website

valneva.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $200M

EBITDA: ($61M)

EV

$637M

Valuation Multiples

Multiples.vc

Start free trial

Valneva Financials

Valneva reported last 12-month revenue of $200M and negative EBITDA of ($61M).

In the same LTM period, Valneva generated $94M in gross profit, ($61M) in EBITDA losses, and had net loss of ($118M).

Valneva P&L

In the most recent fiscal year, Valneva reported revenue of $206M and EBITDA of ($59M).

Valneva expects next 12-month revenue of XXX and NTM EBITDA of XXX

Valneva Stock Performance

Valneva has current market cap of $522M, and enterprise value of $637M.

Valneva's stock price is $3.00.

Valneva Valuation Multiples

Valneva trades at 3.2x EV/Revenue multiple, and (10.4x) EV/EBITDA.

Valneva Financial Valuation Multiples

As of April 18, 2026, Valneva has market cap of $522M and EV of $637M.

Equity research analysts estimate Valneva's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Valneva has a P/E ratio of (4.4x).

Valneva Margins & Growth Rates

Valneva's revenue in the last 12 month grew by 25%.

Valneva's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.

Valneva's rule of 40 is (26%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Valneva's rule of X is (33%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Valneva Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Valneva M&A Activity

Valneva acquired XXX companies to date.

Last acquisition by Valneva was on XXXXXXXX, XXXXX. Valneva acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Valneva Investment Activity

Valneva invested in XXX companies to date.

Valneva made its latest investment on XXXXXXXX, XXXXX. Valneva invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).